Keratoconjunctivitis Sicca — Trial of CF101 to Treat Patients With Dry Eye Disease
Citation(s)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease